GNRH1 and endometriosis: Although GnRH agonists such as leuprorelin are highly effective in relieving endometriosis-associated symptoms, they decrease bone mineral content (due to an estrogen-lowering effect), which limits their use to less than 6 months without an add-back therapy [4].